Compounded GLP-1s for PCOS and diabetes: what the science says

What's this video probably claiming?

Based on the caption and hashtags, @its_me_crissylee is sharing a positive personal experience with mail-order compounded GLP-1 medications, likely semaglutide or tirzepatide, obtained through Lavender Sky Health and Strive Compounding Pharmacy. The video almost certainly frames these medications as life-changing for managing both type 2 diabetes and polycystic ovary syndrome (PCOS). She appears to be transitioning between compounding pharmacies, suggesting she's been on a compounded GLP-1 for some time. The tone reads as a genuine patient testimonial, not a hard sell, but the implicit message is that compounded GLP-1s are a convenient, effective, and accessible alternative to brand-name options like Ozempic or Mounjaro. That framing deserves some scrutiny, particularly around the PCOS angle, which is where social media tends to get well ahead of the clinical evidence.

What does the science actually show?

For type 2 diabetes and weight management, the GLP-1 evidence base is genuinely strong. The SUSTAIN and STEP trial programs showed semaglutide producing 10-15% body weight reduction at 2.4mg weekly doses over 68 weeks (Wilding et al., 2021, NEJM). Tirzepatide data from the SURMOUNT-1 trial pushed that further, with up to 22.5% weight loss at 15mg weekly (Jastreboff et al., 2022, NEJM). For PCOS specifically, the picture is more nuanced. GLP-1 agonists do appear to improve insulin sensitivity and androgen levels in women with PCOS, but most trials are small and short. A 2023 systematic review in Reproductive BioMedicine Online (Cena et al.) found GLP-1 use in PCOS improved BMI, testosterone, and menstrual regularity, but sample sizes rarely exceeded 50 participants. The mechanistic rationale is solid. The long-term, large-scale PCOS-specific trial data is not.

Where does the social media noise diverge from clinical reality?

A few places. First, the compounding piece. Compounded semaglutide and tirzepatide are not FDA-approved drugs. They were permitted under shortage provisions, and the FDA has signaled it considers the shortage for both drugs resolved, meaning the legal landscape for compounding these specific molecules is shifting fast. The FDA issued warning letters to compounders in 2024 over quality and labeling concerns. Second, compounded products are not required to demonstrate bioequivalence to brand-name counterparts. Strive Compounding may produce a quality product, but claims of equivalency would be unverifiable without head-to-head data. Third, the PCOS framing on social media tends to present GLP-1s as a PCOS treatment in their own right, when they are currently used off-label for PCOS and no GLP-1 has an FDA indication for the condition. That is not a reason to avoid them. It is a reason to be honest about what we know versus what we are assuming.

What should you actually know?

If you have PCOS and insulin resistance, a GLP-1 agonist prescribed and monitored by a real clinician is a reasonable conversation to have. The metabolic overlap between PCOS and type 2 diabetes makes the mechanism plausible, and the early data is encouraging. But mail-order compounded medications require due diligence. Check that the compounding pharmacy is PCAB-accredited or operates under a valid 503B outsourcing facility designation. Understand that compounded GLP-1s may differ in inactive ingredients, concentration, and stability from brand-name versions. The FDA's 2024 guidance makes clear that patients and prescribers take on additional risk with compounded products. None of this means they are dangerous or ineffective. It means informed consent matters. If you are managing both diabetes and PCOS with a GLP-1, you should be working with a provider who tracks your HbA1c, androgen levels, and menstrual patterns over time, not just your weight.